Compare Cronos Group Inc (CRON) vs Crispr Therapeutics AG (CRSP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cronos Group Inc vs Crispr Therapeutics AG — how do they compare? Cronos Group Inc trades at $2.74 (market cap $1.02B), while Crispr Therapeutics AG trades at $50.91 (market cap $4.97B). The key difference: Crispr Therapeutics AG is far larger — about 4.9× Cronos Group Inc's market cap, and Cronos Group Inc is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals.
| CRON | CRSP | |
|---|---|---|
Market Cap | $1.02B | $4.97B |
Sector | Health | Health |
52-Week High | $3.27 | $76.78 |
52-Week Low | $1.95 | $44.34 |
Enterprise Value | $203.29M | $3.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRON trades at $2.75, showing no change recently. The stock has a mixed technical outlook with a neutral overall signal but bullish moving averages. Fundamentally, revenue grew to $146.59M in 2025, but net income was negative at -$9.45M. Recent news highlights strong Q1 2026 revenue growth of 40% and expansion of its Spinach brand portfolio, though the company faces intense cannabis sector competition.
Outlook is cautious with growth potential from international expansion and market share gains, but profitability remains a challenge. Risks include regulatory uncertainty and competitive pressures. Analyst sentiment is mixed with 60% hold ratings. The stock presents a speculative opportunity for investors betting on continued top-line growth and eventual margin improvement.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cronos Group Inc
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →
